GET DAILY SIGNALSSIGA Technologies (SIGA): Can the Stock Reach the $5.00 Reference Point?
Key Takeaways
- The central reference point used here is $5.00, a level referenced in financial media as the most recent published price target accompanying a Hold rating on the stock — not an analyst consensus, because SIGA has almost no active traditional sell-side coverage.
- SIGA Technologies, Inc. (SIGA) trades near $3.20, so reaching $5.00 would require roughly a +56% advance, a very large move.
- SIGA is a commercial-stage biodefense pharmaceutical company whose lead product, TPOXX (tecovirimat), is an oral antiviral for smallpox and mpox, sold primarily through lumpy government procurement contracts.
- The strongest supporting factors are a debt-free balance sheet with roughly $155 million in cash, TPOXX's strategic position as one of only two approved U.S. smallpox antivirals, and a coming stockpile-replenishment cycle.
- The biggest risks are the timing of the next U.S. Strategic National Stockpile contract, an EU regulatory review of the mpox indication, and extreme revenue lumpiness.
- For more on this name, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- You can also explore Trending AI Robots to see how algorithmic strategies are positioning across the market.
Establishing the $5.00 Reference Point
SIGA does not currently have a meaningful Wall Street analyst consensus. TipRanks lists zero analysts actively publishing 12-month price targets, and MarketBeat shows only a single rating on the stock. With no reliable aggregate of individual analyst targets to average, this article does not present an "average analyst price target." Instead, it uses $5.00, a price objective that has appeared in financial media as the most recent published target attached to a Hold rating on SIGA.
For context, the range of published views is unusually wide. Independent, commissioned research house Edison Investment Research, which is paid by SIGA, values the company substantially higher — around $11 to $12 per share on a risk-adjusted net present value basis — while ratings agencies such as Weiss Ratings have oscillated between Hold and Sell in 2026. Investors should treat the $5.00 figure as a single reference point from thin coverage, not a broad consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where SIGA Stands Today and the Path to the Target
SIGA trades around $3.20, near the low end of a 52-week range of roughly $2.83 to $9.45. The stock has fallen sharply from its highs, reflecting a market capitalization of roughly $230 million. Reaching $5.00 would imply an advance of about +56% from current levels — a very large move that would require a material shift in the outlook for government procurement rather than incremental earnings improvement.
The path to any recovery runs primarily through the company's relationship with BARDA (the Biomedical Advanced Research and Development Authority) and the U.S. Strategic National Stockpile (SNS). SIGA's revenue is inherently lumpy: fiscal 2025 revenue fell to about $94.6 million from $138.7 million the prior year, because deliveries under the prior contract were largely completed and the next procurement cycle has yet to be awarded. Trailing EPS has turned modestly negative as a result. From what I see, this lumpiness remains the core challenge.
Factors That Could Support a Move Toward the Target
The core support is structural. TPOXX is one of only two antivirals approved in the U.S. for smallpox, and it does not carry the black-box mortality warning of its competitor. Stockpile mandates require holding a set number of treatment courses, and courses delivered around 2020 begin expiring in 2027, creating a natural replenishment need. A renewed multi-year SNS contract remains the single most important catalyst for a re-rating.
The balance sheet is also a buffer: SIGA ended fiscal 2025 with about $155 million in cash and no debt, and it declared a special $0.60-per-share dividend paid in April 2026. Additional support comes from international diversification — including a reported $13 million Asia-Pacific order in early 2026 and a MENA partnership with Hikma — and from BARDA-funded label-expansion programs in pediatric use and post-exposure prophylaxis, which could eventually double the treatment-course intensity.
Risks That Could Keep the Target Out of Reach
The principal obstacle is timing. The next U.S. request for proposal (RFP) has repeatedly slipped, partly reflecting organizational changes within the Department of Health and Human Services, and there is no certainty about its size or duration. Delays directly depress near-term revenue visibility and have already prompted analysts and ratings agencies to lower their views.
In Europe, the CHMP (the EU's Committee for Medicinal Products for Human Use) has been reviewing TPOXX's benefit-risk profile after three mpox trials failed their primary endpoint. A loss or narrowing of the EU mpox indication, while not expected to affect the smallpox label, could disrupt near-term international sales. Finally, revenue concentration in a single government customer and the absence of a recurring dividend make the stock sensitive to any single procurement decision. I’m watching this closely as events unfold.
Technical Levels and Market Structure
Technically, SIGA has been in a prolonged downtrend, with the price trading below its 200-day moving average of roughly $4.49 — a zone that also acts as an initial resistance area on any recovery. The $5.00 target sits just above that average. On the downside, the 52-week low near $2.83 represents the primary support level, while the prior 52-week high near $9.45 reflects how far the stock has de-rated. Any sustained move toward $5.00 would likely need to first reclaim and hold above the $4.50 area.
Time Horizon and Key Items to Monitor
Published price objectives generally reflect a roughly 12-month research horizon, though SIGA's thin coverage makes any single target less meaningful. The items most relevant to the $5.00 question are the issuance and terms of the next BARDA/SNS contract or RFP, the CHMP's final decision on the EU referral procedure, progress on the post-exposure prophylaxis and pediatric programs, and the pace and size of international orders. Quarterly results matter less than procurement announcements, given the company's delivery-driven revenue model.
Final Assessment
Can SIGA reach $5.00? The target is a single published reference point from very thin coverage, not an analyst consensus, and it sits roughly +56% above the current price — a very large move. The bull case rests on a debt-free balance sheet, TPOXX's entrenched strategic position, and an approaching stockpile-replenishment cycle that could re-rate the shares. The bear case rests on procurement timing uncertainty, an EU regulatory review, and extreme revenue lumpiness that has already pushed trailing earnings negative. Investors should watch the next SNS contract and the CHMP decision above all else, and should treat the $5.00 figure as a scenario to monitor rather than a forecast.
Exploring AI Daily Buy/Sell Signals
In my own analysis process, I find Tickeron’s AI Daily Buy/Sell Signals useful for monitoring names with limited traditional coverage like SIGA. The tool applies artificial intelligence to track shifting market conditions and technical behavior across thousands of stocks, helping identify potential turning points more efficiently. It supports tracking trends and momentum in a systematic way without replacing fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SIGA in +6.78% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SIGA advanced for three days, in 231 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 57 cases where SIGA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
SIGA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SIGA as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for SIGA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 35 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
SIGA moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SIGA crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SIGA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for SIGA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.348) is normal, around the industry mean (7.271). SIGA has a moderately low P/E Ratio (-103.333) as compared to the industry average of (0.479). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). SIGA's Dividend Yield (0.774) is considerably higher than the industry average of (0.061). P/S Ratio (4.161) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. SIGA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SIGA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of vaccines and antibiotics for the prevention and treatment of serious infectious diseases
Industry PharmaceuticalsGeneric
Advertisement